11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy

BACKGROUND: Despite their efficacy in the treatment of chronic inflammation, the prolonged application of therapeutic glucocorticoids (GCs) is limited by significant systemic side effects including glucocorticoid-induced osteoporosis (GIOP). 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenton, C. G., Doig, C. L., Fareed, S., Naylor, A., Morrell, A. P., Addison, O., Wehmeyer, C., Buckley, C. D., Cooper, M. S., Lavery, G. G., Raza, K., Hardy, R. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698000/
https://www.ncbi.nlm.nih.gov/pubmed/31420008
http://dx.doi.org/10.1186/s13075-019-1972-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698000/
https://www.ncbi.nlm.nih.gov/pubmed/31420008
http://dx.doi.org/10.1186/s13075-019-1972-1

Ejemplares similares